4basebio PLC has announced the formation of a Strategic Advisory Board (SAB) and the appointment of Dr. Amy Walker as the Chief Operating Officer and a member of the Board of Directors. The SAB, effective from 1 July 2024, is comprised of industry experts Bertrand Coissac, Lawrence Pitcher, and Deborah Barbara, who will provide valuable advice and industry insight to support the company's growth goals and objectives. Dr. Walker, who has a background in molecular biology and gene editing technologies, has been instrumental in the company's growth and has been appointed as the first Chief Operating Officer.
Dr. Walker holds non-executive director Board positions on two other high-growth healthcare companies and has a significant scientific and commercial experience in life sciences. The company also disclosed that Dr. Walker holds 51,506 ordinary shares equating to approximately 0.4 per cent in the Company, and 42,128 options over new ordinary shares in the Company. Dr. Heikki Lanckriet, CEO of 4basebio, expressed excitement about the combined expertise of the SAB members and the appointment of Dr. Walker, stating that their contributions will be invaluable to the company's success.
4basebio is an innovation-driven life biotechnology company focused on accelerating the development of advanced therapy medicinal products (ATMPs) through its high-performance synthetic DNA products and non-viral, cell targeting nucleic acid delivery platform. The company's objective is to become a market leader in the manufacture and supply of high-quality synthetic DNA products for research, therapeutic, and pharmacological use, as well as the development of target-specific non-viral vectors for the efficient delivery of payloads in patients.